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Abstract 
Introduction: Mucosal healing is important in celiac disease (CD) for the prevention of 
complications. However, obtaining duodenal biopsies is invasive, and there is currently no 
reliable surrogate marker for histological remission in clinical practice. We aimed to assess 
the role of a commercially available point of care test (POCT), Simtomax (IgA/IgG-deamidated 
gliadin peptide, Rheinfelden, Switzerland), in detecting persistent villous atrophy in CD.  
Methods: We prospectively recruited patients with CD attending endoscopy for the 
assessment of histological remission. All patients had IgA-endomysial antibodies (EMA), IgA-
tissue transglutaminase antibodies (TTG) and Simtomax performed, and completed a 
validated gluten free diet (GFD) adherence questionnaire validated by Biagi et al. A 
gastroscopy was performed in all patients, with four biopsies taken from the second part of 
the duodenum and one from the duodenal bulb. We compared the diagnostic performance 
of the surrogate markers against duodenal histology as the reference standard. 
Results: A total of 217 patients with CD (70% female, age range 16-83, median age 53) on a 
GFD (median duration 6 years) were recruited from 2013-2017. Eighty-five (39.2%) patients 
had persistent villous atrophy. The sensitivities of Simtomax, TTG, EMA and the adherence 
score in detecting villous atrophy were 67.1%, 44.7%, 37.7% and 24.7% respectively.  
Conclusion: The sensitivity of Simtomax was higher than the other surrogate markers in 
predicting villous atrophy (p=0.0005), although with a lower specificity. In combination with 
clinical and dietetic assessments, Simtomax could serve as a valuable adjunct to aid decision 
making on the necessity of repeat biopsies during follow up consultations, with an additional 
advantage of providing results within 10 minutes. 
  
Introduction 
Celiac disease is a systemic autoimmune disease associated with gastrointestinal and extra-
gastrointestinal symptoms, triggered by gluten in genetically susceptible individuals affecting 
approximately 1% of the general population worldwide.(1, 2) A gluten free diet remains the 
only treatment at present. Strict dietary adherence is often challenging given the ubiquity of 
gluten in Westernized diets and processed foods, with adherence rates reported to vary 
between 42% and 91%.(3-5) Dietary transgression is the commonest cause for non responsive 
celiac disease, (6-8) which can lead to gastrointestinal and extra-gastrointestinal symptoms, 
persistent villous atrophy, complications such as osteoporosis and malabsorption, and a 
worse quality of life. Histological remission is not always achieved in adults, with remission 
rates ranging from 34%-65%.(9-11) This is an important point because persistent villous 
atrophy increases the risk of lymphoproliferative malignancies (HR 2.26) (12) and hip 
fractures (HR 1.67).(13) Consequently, the logical approach for disease monitoring would be 
histological assessment of the duodenum for mucosal healing. However, this method is 
invasive, costly, and carries risks of complications such as bleeding, perforation and 
cardiopulmonary complications from sedation. (14, 15) Furthermore, there is little consensus 
for routine follow up biopsy and the timing of re-biopsy among individual practice and 
national guidelines.(16-19)  
 
There is certainly an unmet need for a reliable surrogate marker for histological remission in 
celiac disease. A myriad of novel markers such as serum intestinal fatty acid-binding protein 
(I-FABP) levels (20), urinary gluten immunogenic peptide,(21) citrulline,(22) fecal fat excretion 
(23), urinary lactulose-to-mannitol excretion ratios, (24)  and the maximum concentration of 
simvastatin in the small intestine (25) have been studied, but none of them are currently used 
in widespread routine clinical practice.  
At present, a combination of dietetic evaluation, symptom assessment and serological titers 
are used during follow up to determine the necessity for a repeat duodenal biopsy. However, 
these non-invasive surrogate markers have been shown to correlate poorly with persistent 
villous atrophy. Previous studies have shown a weak association between histological 
recovery and serology such as tissue transglutaminase antibodies (TTG) and endomysial 
antibodies (EMA).(10, 26-29) Dietary assessment by a specialist dietitian is currently the 
optimal method of measuring adherence,(30) although the method of assessment is not 
standardized. Moreover, there are limited celiac specialist dietitians to provide this service, 
often with long waiting times for patients.  
For all these reasons, a simple and reliable method of assessment to measure dietary 
adherence is needed. A dietary assessment questionnaire was devised by Biagi and colleagues, 
ǁŚŝĐŚĐŽŶƚĂŝŶƐ ?ƐŝŵƉůĞƋƵĞƐƚŝŽŶƐďĂƐĞĚŽŶƚŚĞƉĂƚŝĞŶƚƐ ?ƐƚƌĂƚĞŐǇĨŽƌŐůƵƚĞŶĂǀŽŝĚĂnce rather 
than assessing the amount of gluten ingested. Biagi et al. reported that the adherence score 
identified patients in histological remission, with a positive predictive value of 35.7% and 
negative predictive value of 86.7%.(31) Further studies are required to validate the utility of 
this questionnaire. 
Several point of care tests detecting celiac antibodies have been developed over the past 
decade. Most of the point of care tests detect TTG using lateral flow immunochromotography, 
such as Biocard, Celiac Quick Test and Stick CD1 and 2, with the exception of Simtomax which 
detects deamidated gliadin peptide antibodies (DGP). There is an abundance of studies 
investigating the performance of point of care tests in the diagnosis of celiac disease, with 
sensitivities of the aforementioned point of care tests reported to be 58-100%.(32-40) A 
recent head to head trial of Simtomax, Biocard and Celiac Quick Test demonstrated that 
Simtomax outperformed the other two, with sensitivities of 94.4%, 72.2% and 77.8% 
respectively.(32) On the other hand, there is a paucity of studies examining the role of point 
of care tests in disease monitoring. Previous studies showed the sensitivities were found to 
be 78.9% for Simtomax,(36) and 77.8% (using whole blood) and 93.5% (using serum) for Celiac 
Quick Test in measuring dietary adherence in known celiac disease.(39) However, these 
results should be interpreted with caution due to study limitations, such as using TTG rather 
than duodenal histology as the reference standard.We aimed to evaluate the diagnostic 
performance of Simtomax, a commercially available IgA/IgG-DGP based point of care test, 
TTG, EMA and the adherence questionnaire devised by Biagi et al. in predicting persistent 
villous atrophy in patients with celiac disease on a gluten free diet.  
Methods 
Study design and Patients 
The study took place at the Royal Hallamshire Hospital, Sheffield, U.K., from March 2013-
January 2017. We prospectively recruited patients with biopsy proven celiac disease on a 
gluten free diet who were attending for a gastroscopy on a single celiac disease research list 
for the assessment of histological remission. Written consent for the study was obtained 
before their blood tests and gastroscopies. All patients were tested with IgA-TTG, IgA-EMA, 
total IgA levels and the point of care test, Simtomax, at the endoscopy unit.  The dietary 
adherence questionnaire was completed by the patients at the endoscopy unit. A gastroscopy 
with duodenal biopsies was then performed in all patients.  
Point of care test, Simtomax 
Simtomax is a point of care test for celiac disease manufactured by Augurix Diagnostics, 
Rheinfelden, Switzerland. It detects both IgA-DGP and IgG-DGP, as well as the presence of IgA. 
The assay is based on lateral flow immunochromatography using colloidal gold antihuman 
ĂŶƚŝďŽĚŝĞƐ ĂƐĂ ƐŝŐŶĂů ĚĞƚĞĐƚŽƌ ? ƐĂŵƉůĞ ŽĨ  ? ?ʅůŽĨ ĐĂƉŝůůĂƌǇǀĞŶŽus blood was obtained 
through a simple finger prick technique. The blood sample was then applied to the test device, 
followed by the application of 5 drops of the provided buffer solution. The result was available 
after 10 minutes. Positive results were indicated by the presence of a solid red test line for 
IgA and/or IgG-DGP positivity. A second single red line indicated the presence of IgA. An in-
built red control line ensured a correctly functioning test. 
 
Celiac serology 
TTG antibodies were assayed using enzyme-linked immunosorbent assay (ELISA) kits (Aesku 
Diagnostics, Wendelsheim, Germany). A TTG titer of > 15 U/ml before 20/5/2014, a new cut 
off level of >9 U/ml from 20/5-11/12/2014, and then >7 U/ml from 12/12/ 2014 onwards, 
ǁĞƌĞƌĞŐĂƌĚĞĚĂƐƉŽƐŝƚŝǀĞĂƐƉĞƌƚŚĞŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐŐƵŝĚĂŶĐĞ ?IgA-EMA was detected by 
immunofluorescence on primate esophagus sections (Binding Site, Birmingham, UK). Total 
IgA was measured on a Behring BN2 nephelometer (Haywards Heath, West Sussex, UK).  
Dietary adherence questionnaire 
The validated dietary adherence questionnaire devised by Biagi et al consisted of 4 simple 
questions. It gave a 5 point score (0-4), with scores 3-4 indicating strict dietary adherence, 
and scores 0-2 indicating non-adherence. This questionnaire was administered to the patients 
at the endoscopy unit before their gastroscopy. Please refer to figure 1 for the questionnaire. 
Figure 1: Questionnaire and scoring system devised by Biagi et al. to assess compliance with 
a gluten-ĨƌĞĞĚŝĞƚ ŝŶĐŽĞůŝĂĐƉĂƚŝĞŶƚƐ ?  ‘KĨƚĞŶ ? ?ƚŚĞƉĂƚŝĞŶƚĐŽ ƐƵŵĞƐŐůƵƚĞŶƐŽŽĨƚĞŶƚŚĂƚ
he/she cannot remember ǁŚĞŶ ĂŶĚ ŚŽǁ ŵĂŶǇ ƚŝŵĞƐ ƚŚĂƚ ŚĂƐ ŚĂƉƉĞŶĞĚ ?  ‘ZĂƌĞůǇ ? ? ƚŚĞ
patient consumes gluten only occasionally. She/he can remember when and how many 
times that has happened.  
 
Histological evaluation 
In total, at least 5 biopsies were taken from the duodenum with a single bite per pass 
technique, including at least 1 biopsy from the duodenal bulb and 4 quadrantic biopsies from 
the second part of the duodenum. Each biopsy was fixed in formalin at the time of the 
gastroscopy. Specimens were then processed, orientated and embedded in paraffin wax by 
ƚŚĞ ƉĂƚŚŽůŽŐǇ ĚĞƉĂƌƚŵĞŶƚ ? ^ƚĂŶĚĂƌĚ  ? ʅŵ ƚŚŝĐŬ ƐĞĐƚŝŽŶƐ Ăƚ  ? ůĞǀĞůƐ ǁĞƌĞ ƐƚĂŝŶĞĚ ǁŝƚŚ
haematoxylin and eosin, and reported by gastrointestinal histopathologists without 
knowledge of the Simtomax or serology results. Villous atrophy was graded according to the 
modified Marsh criteria. Patients with March 0-2 histology without villous atrophy were 
considered to be in histological remission for the purpose of diagnostic accuracy calculations. 
Ethical considerations 
The study protocol was approved by the Yorkshire and the Humber Research Ethics 
committee and registered with the local research and development department of Sheffield 
Teaching Hospital NHS Foundation Trust under the registration number STH15416. Written 
consent was obtained from all patients.  
Statistical analysis 
Data were summarized by descriptive statistics, including counts and percentages for 
categorical data and medians and ranges for continuous parameters. The diagnostic accuracy 
of TTG, EMA, Simtomax and the adherence questionnaire in detecting ongoing villous atrophy 
was presented with sensitivity, specificity, positive (PPV) and negative predictive values, 
measuring against duodenal histology as the reference standard. Clopper-Pearson method 
was used to calculate the confidence intervals for the diagnostic test sensitivities.  
Results 
A total of 217 patients with biopsy proven celiac disease on a gluten free diet were recruited 
from 2013-2017 (70% female, age range 16-83, median age 53). The median duration of a 
gluten free diet was 6 years (76.5 months; range: 6-900 months). Eighty-five (39.2%) patients 
had persistent villous atrophy as defined by Marsh grade 3 histology. Sixty-eight (80.0%) 
patients had Marsh 3 villous atrophy in both the duodenal bulb and second part of the 
duodenum, 10 (11.8%) patients had villous atrophy isolated to the duodenal bulb, and 6 (7.1%) 
patients had villous atrophy only in the second part of the duodenum. One patient with Marsh 
3 villous atrophy in the second part of the duodenum could not be graded in the duodenal 
bulb.  There were no invalid  or uninterpretable Simtomax results.  
Amongst patients with persistent villous atrophy, 8 had type 1 refractory celiac disease (age 
range 44-71; median age 51.0; 6 females [75%]), and 4 had type 2 refractory disease (age 
range 57-65; median age 60.0; 1 female [25%]). 
Table 1: the number of patients for each Marsh grade, and the number and proportion of 
patients whose surrogate markers correctly identified the presence (Marsh 3a-c histology) 
or absence (Marsh 0-2 histology) of persistent villous atrophy.  
 Marsh 
0 
Marsh 
1 
Marsh 
2 
Marsh 
0-2 
Marsh 
3a 
Marsh 
3b 
Marsh 
3c 
Marsh 
3a-c 
No. of 
patients 
78 37 17 132 38 24 23 85 
Simtomax 48 
(61.5%) 
23 
(62.2%) 
7 
(41.2%) 
78 
(59.1%) 
21 
(55.3%) 
21 
(87.5%) 
15 
(65.2%) 
57 
(67.1%) 
TTG 73 
(93.6%) 
30 
(81.1%) 
15 
(88.2%) 
118 
(89.4%) 
9 
(23.7%) 
12 
(50.0%) 
11 
(47.8%) 
32 
(37.6%) 
EMA 70 
(89.8%) 
30 
(81.1%) 
14 
(82.4%) 
114 
(86.5%) 
9 
(23.7%) 
16 
(66.7%) 
13 
(56.5%) 
38 
(44.7%) 
Adherence 
score 
69 
(88.5%) 
31 
(83.8%) 
14 
(82.4%) 
114 
(86.4%) 
4 
(10.5%) 
9 
(37.5%) 
8 
(34.8%) 
21 
(24.7%) 
 
 
 
Table 2: The diagnostic performance of Simtomax, TTG, EMA and the adherence score in 
detecting persistent villous atrophy measuring against duodenal histology. 
  Sensitivity (%) Specificity (%) Positive predictive 
value (%) 
Negative predictive 
value (%) 
Simtomax 67.1 (56.0-76.9) 59.1 (50.2-67.6) 51.4 (45.0-57.6) 73.6 (66.6-79.6) 
TTG 44.7 (33.9-55.9) 86.4 (79.3-91.7) 67.9 (56.4-77.5) 70.8 (66.5-74.8) 
EMA 37.7 (27.4-48.8) 89.4 (82.9-94.1) 69.6 (56.5-80.1) 69.0 (65.1-72.6) 
Adherence 
score 
24.7 (16.0-35.3) 86.4 (79.3-91.7) 53.9 (39.8-67.3) 64.0 (60.8-67.2) 
Surrogate markers correctly testing 
positive for villous atrophy. 
Surrogate markers correctly testing 
negative for villous atrophy. 
 Discussion 
This is the largest study that evaluates the point of care test, Simtomax, in disease monitoring. 
One of the strengths of this study is that duodenal biopsies were taken from all patients 
irrespective of their celiac antibody or adherence score results, ensuring that false negative 
cases would be taken into account when calculating the sensitivities and specificities of the 
surrogate markers. The only other published study investigating the role of Simtomax in 
disease monitoring was performed by Benkebil et al. (36) The authors tested Simtomax and 
TTG in 46 patients with known celiac disease, but only those with a positive TTG serology had 
duodenal biopsies taken. The sensitivity and specificity of Simtomax was reported to be 78.9% 
and 95.7% respectively. These results are unlikely to reflect the true performance of 
Simtomax in disease monitoring, as only patients with a positive TTG were biopsied, which 
means false negative cases would be missed.  
 
Deamidated gliadin peptide (DGP) serology has been shown in several studies to be useful for 
disease monitoring in celiac disease, and appeared to be superior to TTG in this respect. (41-
44) Spatola et al. showed that IgG-DGP was an effective surrogate marker for histological 
recovery, with a sensitivity and specificity of 87% and 89% (at a positive threshold of 12U/ml), 
versus 33% and 100% for TTG (at a positive threshold of 5U/ml) when tested on 60 patients 
with known celiac disease who were strictly adherent, of which 15 (20%) had persistent villous 
atrophy. ROC curve analysis showed that IgG-DGP substantially outperformed IgA-TTG with a 
receiver operator curve (ROC) area under the curve (AUC) of 0.94 versus 0.61.(42) Similar 
results were replicated by de ŚĂŝƐĞŵĂƌƚŝŶ ?Ɛ ŐƌŽƵƉ ƐƵďƐĞƋƵĞŶƚůǇ, with a ROC analysis 
demonstrating AUC 0.817 for IgG-DGP in detecting ongoing villous atrophy.(44)  
 Although the sensitivity of Simtomax was significantly higher than TTG in our study 
(p=0.0005), Simtomax alone is still inadequate as a surrogate marker for ongoing villous 
atrophy. It is not clear why there is such marked difference between the performance of 
Simtomax and IgG-DGP serology as previously reported.(42, 44) It is conceivable that the 
serological cut off value for untreated celiac disease is not appropriate for disease monitoring 
purposes, and the threshold for the generation of a positive result in Simtomax cannot be 
adjusted like laboratory serological titers to identify the optimal cut off numerical value.  
 
Table 1 shows the performance of the surrogate markers across the range of Marsh grades, 
demonstrating where the true positives/negatives and false positives/negatives lie within the 
Marsh grade spectrum. TTG, EMA and the adherence score generally faired better in correctly 
identifying patients in histological remission (Marsh 0-2), but missed a relatively large 
proportion of patients with villous atrophy (higher rates of false negatives). Conversely, 
Simtomax performed better in detecting patients with villous atrophy than correctly 
identifying those in remission (higher rates of false positives). For a disease monitoring 
surrogate marker, it is more important to have a high sensitivity than a high specificity, as the 
priority is to identify patients with ongoing villous atrophy which can lead to serious 
complications, whilst accepting a certain degree of false positives as a drawback. 
 
Although Simtomax outperformed the other surrogate markers, it is not sensitive enough to 
be used in isolation during follow up. However, we believe that by combining dietetic 
evaluation and symptom assessment, Simtomax could serve as a useful adjunct to provide 
instant DGP results during a follow up consultation, not only for the benefit of the clinicians, 
but also immediate feedback for the patients which they highly value. Currently, patients 
have their celiac serology taken on the day of their follow up consultation, and the results 
usually takes 3- ? ĚĂǇƐ Žƌ ŵŽƌĞ ƚŽ ƚƵƌŶ ĂƌŽƵŶĚ ? dŚŝƐ ĂĚĚƐ ƚŽ ƚŚĞ ĐůŝŶŝĐŝĂŶ ?Ɛ ĂĚŵŝŶŝƐƚƌĂƚŝǀĞ
burden to communicate the results with the patients retrospectively, and it also often causes 
delays in clinical decision making regarding the management plan. With the use of a point of 
care test during a clinic consultation, a face to face discussion between the clinician and the 
patient making a joint decision regarding the need for re-biopsy or a dietetic review is made 
possible.  
The low sensitivity of 44.7% for IgA-TTG in detecting persistent villous atrophy in our study is 
in line with what has been reported in the literature. For instance, Kaukinen et al. reported 
the IgA-TTG sensitivity to be 41%,(26) ĂŶĚŵŽƌĞƌĞĐĞŶƚůǇ ? ? ? ?A?ďǇ^ŚĂƌŬĞǇ ?ƐŐƌŽƵƉ ?(10) The 
even lower sensitivity of 37.7% for IgA-EMA also mirrors the 26% sensitivity reported by 
Kaukinen et al. (26)  
The dietary adherence questionnaire was quick and simple to administer, although its 
performance in identifying patients with ongoing villous atrophy was disappointing in our 
study. A recent study by Bannister et al. evaluated this adherence questionnaire and found 
that the adherence score had a similarly low correlation to villous atrophy, with a sensitivity, 
specificity, positive and negative predictive values of 33%, 89%, 13% and 97% respectively.(45) 
The sensitivity and specificity of the adherence score were consistent with our results of 
24.7% and 86.4%, however the positive and negative predictive values were strikingly 
different from our findings. This could be due to the significantly lower prevalence of 
ƉĞƌƐŝƐƚĞŶƚǀŝůůŽƵƐĂƚƌŽƉŚǇŝŶĂŶŶŝƐƚĞƌ ?Ɛpediatric cohort (5.3%) compared to our adult cohort 
(39.2%), where a low prevalence population could lead to a high negative predictive value for 
a diagnostic test.  Indeed, previous follow up studies have demonstrated a slower and more 
incomplete mucosal healing in adults with celiac disease treated with a gluten free diet. (11, 
46-48) Potential reasons for the low sensitivity of the adherence questionnaire include  
reliance on the patient understanding of what foods contain gluten and their 
forthcomingness.  
To conclude, this study showed for the first time that the commercially available DGP based 
point of care test, Simtomax, had a superior sensitivity in detecting persistent villous atrophy 
in patients with known celiac disease, compared to the adherence score and conventional 
celiac serology (TTG and EMA) which are routinely used for disease monitoring at the present 
time. Simtomax could help streamline the follow up process by providing DGP results during 
the consultation, and facilitate the decision making between the clinician and the patient 
regarding the onward management plan such as the necessity of follow up duodenal biopsy. 
WHAT IS CURRENT KNOWLEDGE 
- Persistent villous atrophy in celiac disease increases the risk of complications in celiac 
disease.  
- There are currently no reliable surrogate markers for persistent villous atrophy.  
WHAT IS NEW HERE 
- Simtomax has significantly higher sensitivity than conventional serology in detecting 
persistent villous atrophy. 
- Simtomax could provide instant DGP results during follow up consultations to 
facilitate onward management. 
- The validated dietary adherence questionnaire was inferior to Simtomax and serology 
in identifying ongoing villous atrophy. 
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